Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Will Change ‘All-Day’ Vitamin Name Following Ad Board Decision

This article was originally published in The Tan Sheet

Executive Summary

Bayer Healthcare will change the name of itsAll-Day Energy multivitamin/multimineral product under the One-A-Day line in response to recommendations from the National Advertising Review Board

You may also be interested in...



Bittersweet Decision For Prestige In Little Remedies Honey Claims Review

Robitussin pediatric OTCs marketer Pfizer contends in a NAD review that the brand Little Remedies is a “therapeutic effectiveness” claim because “remedy” is a “medicine, application, or treatment that relieves or cures a disease.” NAD takes a narrower view of the brand’s use of the term.

Bittersweet Decision For Prestige In Little Remedies Honey Claims Review

Robitussin pediatric OTCs marketer Pfizer contends in a NAD review that the brand Little Remedies is a “therapeutic effectiveness” claim because “remedy” is a “medicine, application, or treatment that relieves or cures a disease.” NAD takes a narrower view of the brand’s use of the term.

Bayer Takes On NAD In All-Day Energy Claims Challenge Brought By Wyeth

Bayer Healthcare will take a second opportunity to present evidence for the continued use of the All-Day Energy brand for its multivitamin product, according to a July 12 decision by the National Advertising Division of the Council of Better Business Bureaus

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101287

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel